Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Line Extensions Cause Confusion, Medical Errors, USP Members State

This article was originally published in The Tan Sheet

Executive Summary

A resolution concerning the reduction of medical errors through labeling and packaging standards would apply to OTC drugs, the U.S. Pharmacopeia's Resolutions Committee decided at USP's quinquennial meeting in Washington, D.C. April 12-16.

You may also be interested in...



Brand Name Confusion Preventable Under Existing Regs, Industry Rep Says

Established brand history and OTC labeling rules provide consumers with enough information to avoid confusing self-care products carrying similar brand names and different active ingredients, Consumer Healthcare Products Association General Counsel Eve Bachrach told an FDA panel June 28.

Brand Name Confusion Preventable Under Existing Regs, Industry Rep Says

Established brand history and OTC labeling rules provide consumers with enough information to avoid confusing self-care products carrying similar brand names and different active ingredients, Consumer Healthcare Products Association General Counsel Eve Bachrach told an FDA panel June 28.

Brand Name Confusion Preventable Under Existing Regs, Industry Rep Says

Established brand history and OTC labeling rules provide consumers with enough information to avoid confusing self-care products carrying similar brand names and different active ingredients, Consumer Healthcare Products Association General Counsel Eve Bachrach told an FDA panel June 28.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel